NervGen Pharma Corp. (NGEN)vsRevolution Medicines Inc (RVMD)
NGEN
NervGen Pharma Corp.
$3.63
-3.20%
HEALTHCARE · Cap: $311.58M
RVMD
Revolution Medicines Inc
$140.55
-2.96%
HEALTHCARE · Cap: $29.88B
Smart Verdict
WallStSmart Research — data-driven comparison
RVMD leads profitability with a 0.0% profit margin vs 0.0%. RVMD earns a higher WallStSmart Score of 24/100 (F).
NGEN
Avoid17
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Safe zone — low bankruptcy risk
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Trading at 17.0x book value
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : NGEN
NGEN has a balanced fundamental profile.
Bull Case : RVMD
The strongest argument for RVMD centers on Altman Z-Score.
Bear Case : NGEN
The primary concerns for NGEN are Revenue Growth, EPS Growth, Market Cap.
Bear Case : RVMD
The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.
Key Dynamics to Monitor
RVMD carries more volatility with a beta of 1.01 — expect wider price swings.
NGEN is growing revenue faster at 0.0% — sustainability is the question.
NGEN generates stronger free cash flow (-10M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
RVMD scores higher overall (24/100 vs 17/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
NervGen Pharma Corp.
HEALTHCARE · BIOTECHNOLOGY · USA
Nanogen Inc (NGEN) is a cutting-edge biotechnology company dedicated to advancing molecular diagnostic technologies aimed at improving patient outcomes through innovative genomic analysis solutions. The firm specializes in the development and commercialization of products tailored to complex disease targets, utilizing its proprietary platforms to deliver precise and timely diagnostics. With a robust focus on research and development, Nanogen is poised to expand its portfolio and drive growth in the dynamic diagnostic market, aligning with the industry's shift toward personalized medicine and the increasing demand for sophisticated diagnostic tools.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?